Metronomic Maintenance Therapy for Rhabdomyosarcoma
- PMID: 31813450
- DOI: 10.1016/j.trecan.2019.10.004
Metronomic Maintenance Therapy for Rhabdomyosarcoma
Abstract
In a recent article, Bisogno et al. reported in a randomized trial that addition of metronomic maintenance therapy (MMT) with vinorelbine plus cyclophosphamide for children with rhabdomyosarcoma resulted in a significant increase in overall and event-free survival. Although the mechanism of action remains to be fully elucidated, this study paves the way for further evaluation of MMT as a potential therapeutic strategy in pediatric patients with high-risk disease.
Keywords: angiogenesis; chemotherapy; immunity; maintenance; metronomic; microenvironment; rhabdomyosarcoma.
Copyright © 2019 Elsevier Inc. All rights reserved.
Comment on
-
Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol. 2019 Nov;20(11):1566-1575. doi: 10.1016/S1470-2045(19)30617-5. Epub 2019 Sep 24. Lancet Oncol. 2019. PMID: 31562043 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources